Skip to main content
Evidence Snapshot

Canis familiaris

CHEMBL373 ORGANISM Canis lupus familiaris
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:53:54Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL373
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Canis familiaris as ChEMBL target CHEMBL373. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Canis familiaris
ORGANISM · Canis lupus familiaris
As of 2026-09-13
ChEMBL target ID
CHEMBL373
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Canis familiaris matters

As of 2026-09-13

Canis familiaris is reviewed as Canis familiaris; the current evidence base includes 12 approved drugs, 9378 compounds, and 16332 assays, with lead potency reaching pChEMBL 10.1.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 12 approved drugs, 9378 compounds, and 16332 assays for this target. The dominant activity type is EC50. CHEMBL603358 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL603358 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine
12 approved pChEMBL 10.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Canis familiaris matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

9378
Total Compounds
16332
Total Assays
12
Approved Drugs
IC50: 136.0, KI: 1.0, EC50: 207.0, KD: 76.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL603358
 10.1 EC50 —
No preferred name
CHEMBL477
 9.9 EC50 Approved
No preferred name
CHEMBL2093995
 9.7 EC50 —
No preferred name
CHEMBL2093996
 9.7 EC50 —
No preferred name
CHEMBL603362
 9.6 EC50 —

Approved Drugs

Structure Compound First Approval
ETRASIMOD
CHEMBL3358920
 2023
ALFUZOSIN
CHEMBL709
 2003
TAMSULOSIN
CHEMBL836
 1997
SUMATRIPTAN
CHEMBL128
 1992
DOXAZOSIN
CHEMBL707
 1990
ADENOSINE
CHEMBL477
 1989
TERAZOSIN
CHEMBL611
 1987
MILRINONE
CHEMBL189
 1987
NITROGLYCERIN
CHEMBL730
 1981
PROPRANOLOL
CHEMBL27
 1967
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:53:54Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL373